Notably, codon 13 mutations, specifically G13D, have a slightly better prognosis, and some studies suggest that CRC patients with G13D mutations may benefit from certain EGFR inhibitors, such as cetuximab [31,32,33]. This evidence concerns the gene EGFR and colorectal carcinoma.